Common Meds Linked to Reduced Immunotherapy Benefit in Lung Cancer Trial

[ad_1]

(MedPage Today) — Exposure to proton pump inhibitors (PPIs) was associated with worse progression-free survival (PFS) and overall survival (OS) in patients with locally advanced non-small cell lung cancer (NSCLC) who were treated with durvalumab…

[ad_2]

Source link : https://www.medpagetoday.com/hematologyoncology/lungcancer/122068

Author :

Publish date : 2026-07-06 20:38:00

Copyright for syndicated content belongs to the linked Source.